The trial aims to combine personal information, pharmacogenomics data, and machine-learning tools to select the best anti-seizure medication for patients.
Researchers have tied nearly 200 candidate genes, including ones involved in neurodevelopment, apoptosis, and inflammation, to the volume of brain structures.
This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.
